Enprofylline
Chemical compound
- None
- 3-Propyl-7H-purine-2,6-dione
- 41078-02-8 Y
- 1676
- DB00824 N
- 1613 Y
- DT7DT5E518
- D04006 N
- CHEBI:126237 N
- ChEMBL279898 N
- DTXSID9045186
- Interactive image
- CCCn2c(=O)[nH]c(=O)c1nc[nH]c12
InChI
- InChI=1S/C8H10N4O2/c1-2-3-12-6-5(9-4-10-6)7(13)11-8(12)14/h4H,2-3H2,1H3,(H,9,10)(H,11,13,14) Y
- Key:SIQPXVQCUCHWDI-UHFFFAOYSA-N Y
Enprofylline (3-propylxanthine) is a xanthine derivative used in the treatment of asthma, which acts as a bronchodilator. It acts primarily as a competitive nonselective phosphodiesterase inhibitor with relatively little activity as a nonselective adenosine receptor antagonist.[1][2]
References
- ^ Lunell E, Svedmyr N, Andersson KE, Persson CG (1982). "Effects of enprofylline, a xanthine lacking adenosine receptor antagonism, in patients with chronic obstructive lung disease". European Journal of Clinical Pharmacology. 22 (5): 395–402. doi:10.1007/bf00542541. PMID 6288396. S2CID 3240010.
- ^ Laursen LC (December 1987). "Anti asthmatic effects and pharmacokinetics of enprofylline--a new xanthine derivate". Danish Medical Bulletin. 34 (6): 289–97. PMID 3325233.
- v
- t
- e
Short-acting β2 agonists | |
---|---|
Long-acting β2 agonists |
|
Ultra-long-acting β2 agonists | |
Other |
muscarinic antagonist
Leukotriene antagonists | |
---|---|
Arachidonate 5-lipoxygenase inhibitors | |
Thromboxane receptor antagonists | |
Non-xanthine PDE4 inhibitors |
- Aclidinium bromide/formoterol
- Beclometasone/formoterol
- Beclometasone/formoterol/glycopyrronium bromide
- Budesonide/formoterol
- Budesonide/glycopyrronium bromide/formoterol
- Fluticasone furoate/umeclidinium bromide/vilanterol
- Fluticasone furoate/vilanterol
- Fluticasone propionate/salmeterol
- Glycopyrronium bromide/formoterol
- Indacaterol/glycopyrronium bromide
- Indacaterol/glycopyrronium bromide/mometasone
- Indacaterol/mometasone
- Ipratropium bromide/salbutamol
- Mometasone/formoterol
- Salbutamol (albuterol)/budesonide
- Theophylline/ephedrine
- Theophylline/ephedrine/hydroxyzine
- Theophylline/ephedrine/phenobarbital
- Umeclidinium bromide/vilanterol
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III